NewLake Capital Partners, Inc. financials

NLCP CIK 0001854964

Source: EDGAR filings · Built 2026-06-19T01:18:46Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021
EBITDA 42.77M 41.51M 38.92M 35.34M 19.59M
Net Debt -16.22M -12.49M -24.66M -43.95M -127.10M
Operating Margin 53.36% 53.45% 52.12% 50.04% 40.97%
Net Margin 51.53% 52.09% 51.97% 48.84% 41.30%
Return on Equity (ROE) 6.78% 6.58% 6.08% 5.19% 2.71%
Return on Assets (ROA) 6.25% 6.05% 5.67% 4.84% 2.51%
Debt-to-Equity 0.02× 0.02× 0.00× 0.00× 0.00×
Cash Conversion Ratio 1.61× 1.66× 1.63× 1.68× 2.30×
Accruals Ratio -0.04× -0.04× -0.04× -0.03× -0.03×
SBC % of Revenue 2.09% 3.34% 3.04% 3.32% 7.20%

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021
Revenues 51.07M 50.13M 47.30M 45.00M 28.06M
Operating Expenses 23.83M 22.87M 22.48M 22.42M 16.56M
Operating Income (Loss) 27.25M 26.79M 24.66M 22.52M 11.49M
Net Income (Loss) Attributable to Parent 26.32M 26.11M 24.59M 21.98M
Earnings Per Share, Basic $1.28 $1.27 $1.16 $1.03 $0.66
Weighted Average Number of Shares Outstanding, Basic 20.62M 20.56M 21.17M 21.42M 17.01M
Earnings Per Share, Diluted $1.28 $1.27 $1.16 $1.03 $0.65
Weighted Average Number of Shares Outstanding, Diluted 20.99M 20.96M 21.55M 21.81M 17.57M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021
Cash and Cash Equivalents, at Carrying Value 23.94M 20.21M 25.84M 45.19M 127.10M
Assets 420.83M 431.54M 433.29M 454.25M 460.88M
Liabilities 26.14M 27.56M 21.34M 23.31M 21.55M
Stockholders' Equity Attributable to Parent 387.94M 396.76M 404.58M 423.55M 427.56M
Common Stock, Shares, Outstanding 20.55M 20.51M 20.50M 21.41M 21.24M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021
Net Cash Provided by (Used in) Operating Activities 42.46M 43.35M 40.08M 37.01M 26.70M
Net Cash Provided by (Used in) Investing Activities -1.49M -19.14M -12.84M -86.45M -39.91M
Payments for Repurchase of Common Stock 0 11.81M 0
Net Cash Provided by (Used in) Financing Activities -37.25M -29.84M -46.60M -32.46M 120.69M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (NLCP CIK 0001854964), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

AVHHL

AVITA MEDICAL, INC.

HPAIW

Helport AI Limited

RKTO

Hoth Therapeutics, Inc.